Related Experiment Videos

C-erbB2, p27 and G1/S aberrations in human primary breast cancer

Martin Lodén1, Frans Perris, Niels Hilmer Nielsen

  • 1Department of Pathology, Umea University, S-901 87 Umea, Sweden.

Anticancer Research
|August 5, 2003
PubMed
Abstract

Insights

C-erbB2 overexpression in breast cancer is linked to poor survival and cell cycle changes. However, its direct role in proliferation varies by tumor subtype, suggesting diverse functions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • C-erbB2 (human epidermal growth factor receptor 2) overexpression occurs in ~25% of breast cancers.
  • While linked to cell cycle regulators like p27, D cyclins, and c-myc, the precise relationship between C-erbB2 and proliferation via the pRb pathway in primary breast cancer remains unclear.

Purpose of the Study:

  • To investigate the relationship between C-erbB2 expression and cell cycle proteins, including the pRb pathway.
  • To determine the association between C-erbB2 and proliferation in primary breast tumors.

Main Methods:

  • Expression analysis of C-erbB2 and various cell cycle proteins in 105 primary breast tumors.
  • Correlation of C-erbB2 expression with clinical parameters and proliferation markers.

Main Results:

  • C-erbB2 overexpression correlated with p27 downregulation and poorer survival.
  • No overall correlation was found between C-erbB2 and proliferation.
  • An association between C-erbB2 and proliferation was observed in specific subtypes: estrogen-receptor-positive tumors, those with high cyclin D1, and those with a linear pRb pathway.

Conclusions:

  • C-erbB2 may exert alternative functions in different breast cancer subtypes.
  • Beyond promoting proliferation, C-erbB2 likely influences breast cancer progression through additional mechanisms.

Related Concept Videos